Cuorips

Cuorips Inc. introduces its iPS cell-derived cardiac muscle sheet, LiHaRT, which received manufacturing and marketing approval in March 2026.

Cuorips Inc. showcases its proprietary technology, intellectual property, and manufacturing capabilities to deliver regenerative medicine to all patients.

Nikkei BioTech Online published an article on Cuorips Inc.’s commercial cell culture processing facility, CLiC-1, and its expansion into contract manufacturing in Minoh City.

Qualips Corporation introduces its regenerative medicine efforts, aiming to create a world where heart disease is no longer fatal.

Cuorips Inc. outlines its corporate governance framework, including management transparency, decision-making efficiency, and compliance policies.

Qualips develops next-generation cell manufacturing to meet future demand, strengthening Japan’s industrial and global competitiveness.

Cuorips Inc. develops and manufactures regenerative medicine products using iPS cell technology, including commercialized cardiomyocytes and contract manufacturing services.

Cuorips Inc. explains how it handles personal data, including usage, third-party sharing, and correction procedures, to ensure robust protection.

Cuorips Inc. details its privacy policy, emphasizing compliance with laws and secure management of personal data for iPS cell-based regenerative medicine.

Cuorips Inc. provides disclaimers for its investor relations information, clarifying assumptions, risks, and accuracy of forward-looking statements.

Cuorips Inc. publishes its policy against antisocial forces, rejecting all ties and demands while ensuring compliance and transparent operations.

Japan’s health ministry conditionally approves the first regenerative medical products globally using induced pluripotent stem (iPS) cells. The products mark a milestone in stem cell therapy, enabling advanced medical treatments based on patient-specific cells. Approval covers both production and sales under regulatory oversight.

Mar 2026nationthailandNews article

Japan’s health ministry conditionally approves the first two regenerative therapies using induced pluripotent stem (iPS) cells. The therapies mark a global milestone in stem cell-based medical treatments, allowing production and sales under regulatory oversight. The decision follows years of research and clinical trials in Japan.

Mar 2026Tuoi tre newsNews article

Japan’s Kuoripseu commercializes cardiac muscle sheets derived from iPS cells, a Nobel-winning technology. The company develops a mini heart model to showcase its product, *Rihateu*, a cardiac muscle sheet. This innovation was demonstrated at last year’s Osaka and Kansai Expo.

Feb 2026The Asia Business DailyNews article

Cuorips Inc. submits Japan’s first marketing authorization application for a regenerative medicine product using **iPS-derived cardiomyocyte sheets**, targeting heart repair. The Osaka University-spun biotech venture seeks approval from the Ministry of Health, Labour and Welfare (MHLW) for its stem-cell-based therapy. This marks a global first for commercializing iPS cell applications in regenerative medicine.

Apr 2025worldinsight.comNews article